The health insurance company Aetna said it will waive co-pays for the opioid overdose antidote Narcan (naloxone) starting in January, CNN Money reports.
“Aetna is committed to addressing the opioid crisis through prevention, intervention and treatment,” Harold L. Paz, MD, MS, Executive Vice President and Chief Medical Officer of Aetna said in a news release. “Increasing access to Narcan can save lives so that individuals with opioid abuse disorder can live long enough to get into evidence-based treatment.”
According to research from the company that makes Narcan, almost 35 percent of Aetna members prescribed the drug between January to June 2017 did not pick up their prescription.
Members are less likely to fill Narcan prescriptions as co-pays increase. “Cost is clearly a factor in whether individuals with substance abuse disorder obtain medication that could save them from a fatal overdose,” Paz said. “By eliminating this barrier, we hope to keep our members safe until they are ready to address their addiction.”